Trials / Completed
CompletedNCT00687622
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects With Solid Tumors or Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 206 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
MEK111054 is a first-time-in-human, open-label study to determine recommended dose and regimen for the orally administered GSK1120212. The study consists of three parts. Part 1 will identify the maximum tolerated dose. Part 2 will explore the safety, tolerability, and effectiveness of GSK1120212. Part 3 will determine a range of effective doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK1120212 | Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses |
Timeline
- Start date
- 2008-07-28
- Primary completion
- 2011-06-07
- Completion
- 2011-11-08
- First posted
- 2008-06-02
- Last updated
- 2017-11-13
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00687622. Inclusion in this directory is not an endorsement.